Tracy Bell

  • Citations Per Year
Learn More
PURPOSE PARP is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate topoisomerase I inhibitor-mediated DNA damage. This phase I study determined the MTD, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics (PD) of veliparib, an orally bioavailable PARP1/2 inhibitor, in combination with(More)
Correspondence: Patricia M. LoRusso, D.O., Associate Center Director – Innovative Medicine, Yale Cancer Center, WWW217, 333 Cedar Street, New Haven, CT 06510; Phone: 203-785-5944; Fax: 203-785-4116; or Geoffrey I. Shapiro, M.D., Ph.D., Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer(More)
  • 1